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Abstract 
 
Thyroid pathology is the commonest endocrine surgical problem encountered. However, the study of thyroid stem 
cells is relatively new in the field of stem cell research. Since the identification of thyroid stem cells in 1992, 
research interest in this area has been increasing mainly based on furthering our knowledge of the biology of these 
important cells that are thought to be responsible for tumourigenesis and propagation of cancers. This article reviews 
the current science and biology of thyroid stem cells and summarizes their potential role in the general management 
of thyroid disorders. 
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Introduction 
 
Thyroid nodular disease, either symptomatic or 
incidental, is the most common endocrine surgical 
disorder encountered. Nodules are not a single disease 
entity but represent a wide range of pathological 
processes ranging from the normal physiological 
process to lethal malignancy (1). The main 
pathophysiological process that drives the formation of 
these nodules is attributed to chronic stimulation of 
thyrocytes via the thyrotropin hormone receptor 
(TSHR) and its downstream signaling cascade. In one 
population based study, it was noted that the incidence 
of thyroid cancer increased with higher TSH and 
interestingly, high level of TSH is associated with 
more advanced differentiated cancers (2). Thyroid 
nodular disease is also one of the predisposing factors 
for development of thyroid cancer, although this 
relationship is still not clearly understood. 
 
The worldwide incidence of thyroid cancer has 
progressively risen over the past three decades by an 
average of 4.5% each year from 2002 to 2012 in the 
USA (3,4). While this can partly be attributed to the 
ease of access to thyroid sonography that has resulted 
in more sensitive detection, more accurate diagnostics 
work up and increasing patient awareness are other 
contributing factors. With this steady upward trend, 
detection of smaller cancers (i.e. micropapillary 
carcinoma) becomes an increasingly common scenario 
(5)  and this may result in  thyroid cancer becoming 
the third most common cancer in the United States by 
2030 (6,7). Despite the increasing reported incidence, 
mortality due to thyroid cancers has been stable at 0.3 
and 0.6 per 100,000 population in men and women, 
respectively in high-resourced countries (7).  
 
The mortality from thyroid cancer is mainly attributed 
to the more radio-resistant, recurrent, differentiated
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Figure 1: Schematic diagram of the classical self-renewal and differentiation properties of stem cells (SC). Symmetric division 
occurs when SC divides into two similar progenitor cells or SC, whilst asymmetric division occurs when SC divides into one 
identical SC and another daughter cell that becomes differentiated cell. 
 
cancers with/without metastasis and anaplastic, poorly 
or undifferentiated thyroid cancers. In anaplastic 
cancers, the 5-year survival is often very poor at <5%. 
It is thus, reasonable to focus future research on these 
tumours in order to improve survival. In radio-resistant 
cancers, the tumour cells are thought to have changed 
their phenotype to a less differentiated phenotype that 
makes them less susceptible to I131 treatment (8). The 
remaining modes of treatment with chemotherapeutic 
drugs and external beam radiation are often poorly 
tolerated and rarely curative (9,10). One possible 
reason for the development of these resistant tumours 
could be due to the presence of cells that have the 
capability to self-divide, metastasize and resist 
chemotherapeutic interventions. These properties 
mimic closely those of stem cells (11,12). 
 
Stem Cells 
 
Stem cells are fundamental cells from which all our 
cells arise or ‘stem’ from. These unique 
undifferentiated cells have the properties to divide 
and thus renew themselves for very long period of 
time in the body and in vitro (13). They are broadly 
classified into embryonic stem cells (ESC) and 
somatic/adult stem cells based on their differentiation 
potential (potency). The pluripotent ESC can 
differentiate into any of the three germ layers i.e. 
endoderm (gastrointestinal tract and its derivatives 
e.g. lung, liver, pancreas and thyroid), mesoderm 
(muscle, bone, blood and cardiovascular system) and 
ectoderm (skin and nervous system). However, this 
ability is limited in adult stem cells. While there is no 
doubt that the therapeutic potential of ESC seems 
limitless, the ethical implications that surround their 
use have restricted their application in clinical 
practice.  
Stem cells are able to divide giving rise to similar 
progenitor cells (symmetric division) or 
asymmetrically. Asymmetric division allows for two 
different daughter cells to be produced, one to 
replenish the stem cell pool and the other to become a 
differentiated cell, so the stem cell daughter would be 
capable of generating more stem cells (Fig. 1). This 
clonogenic capacity contributes to the presence of cell 
heterogeneity within tissues and ensures homeostatic 
control within tissues is maintained (13). In order to 
retain and safe guard this special feature, stem cells 
need to reside in a specific microenvironment called 
the niche (14). 
 
There are a number of transcriptional regulatory 
circuits which are responsible for maintaining 
pluripotency and self-renewal capability in stem cells 
(15). Homeodomain transcription factors are 
evolutionary conserved and play important roles in cell 
fate (16). Oct4/POU5F1 and NANOG are essential 
regulators of early development and their expression 
provides evidence of embryonic stem cell identity 
(17,18). OCT4 acts in concert with another 
transcription factor SOX2. Their combination is 
thought to be fundamental in developmental control of 
gene expression involved in pluripotency. 
 
It was reported that OCT4 controls pluripotency in a 
quantitative manner, that is when expressed at high 
levels in embryonic stem cells OCT4 drives these cells 
to endoderm and mesoderm lineages (19). Among 
these widely studied core transcriptional factors, 
OCT4 has been found to be indispensable in the 
maintenance of pluripotency (20).  
 
With their specialised roles, stem cells have been 
identified as important players in regeneration, fibrosis 
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and cancer development and progression. The use of 
adult SC in regenerative treatment in clinical practice 
e.g. limbal transplantation and cardiac regeneration 
has shown promising results (21,22). However, their 
impact in solid cancer management is still under 
investigation due to challenges in identifying clinically 
relevant biomarkers to specifically target cancer SC 
(23). 
 
Normal Thyroid SC 
 
Over the past decade, a number of investigators have 
reported on the identification of putative human 
thyroid stem/progenitor cells. The presence of thyroid 
SC populations was first postulated by Dumont  et al. 
(24), who found that it was possible to grow thyroid 
tissue in recipient animals using only a minimum 
number of cells. This idea was further elaborated and 
reinforced by Thomas et al. (25) and Fierabracci et al. 
(26) who identified precursor cells of endodermal 
origin and isolated a specific subset of cell populations 
from goitrous nodules that have the ability for clonal 
expansion respectively. These cells detected by flow 
cytometry comprise of less than 1.5% of human 
thyroid tissues and lack the expression of thyroid 
specific markers such as thyroglobulin (Tg). 
 
Human thyrocytes have a slow turnover rate 
(estimated at 8.5 to 14.4 years) (27) with limited 
regeneration capacity. Furthermore, thyroid SC niches 
have not been demonstrated in thyroid tissues unlike 
the brain (28) and intestines (29). Due to these facts, 
other than the mature follicular cells, the source of 
thyroid SC has been postulated to derive from 
embryological remnants (30), microchimerism (31) 
and SC from bone marrow (32). 
 
There was a forward leap in the study of thyroid stem 
cells a few years ago, when Antonica et al. 
successfully demonstrated the ability of murine ESC to 
differentiate into a functional thyrocytic lineage in 
vitro. These cells were able to support hormone 
deficiency when transplanted under the renal capsules 
in athyroid mice (33).  
 
Cancer Stem Cells (CSC) 
 
The cancer stem cells (CSC) theory was first 
introduced in the study of haematological 
malignancies (34) where a small population of cells 
was found to constitute a reservoir of self-sustaining 
cells with exclusive ability to self-renew, maintain the 
tumour and also produce heterogenous non-
tumourigenic cancer cell types that constituted the 
bulk of the tumour (35). Due to these properties, SC 
are able to multiply uncontrollably, metastasize and 
resist chemotherapeutic interventions resulting in 
treatment resistance. 
 
The advancement of CSC theory in solid malignancy 
however lagged behind until 5 years later when 
Ignatova et al. identified clonogenic, stem-like cells in 
human cortical gliomas, providing the first evidence of 
CSC in solid cancers (36). Other solid tumours with 
established SC properties were later identified in 
breast (37), prostate (38), colon (39) and pancreas (40). 
For thyroid cancers, a small percentage of CSC has 
been successfully isolated from both tissues and cell 
lines (41-44).  
 
Takano has put forward the notion of fetal cell 
carcinogenesis, which suggests that thyroid cancer 
cells arise from abnormal development of fetal thyroid 
cells possibly secondary to genetic mutations (45). 
This is based on gene expression profiling data seen in 
anaplastic thyroid cells, where onco-fetal fibronectin 
was found to be highly expressed in conjunction with 
lack of expression of differentiated thyroid markers 
(46). Another aspect involved in thyroid 
carcinogenesis relates to the CSC theory. Thyroid CSC 
was first isolated by Mitsutake et al. who postulated 
that the presence of a small subset of cells in the 
mature thyroid is responsible for cancer initiation and 
maintenance (42). At this point, it is not clear whether 
the origin of this subset of cells is normal cells that 
have undergone transformation, or existing stem cells 
that have become activated (47). 
 
The CSC model has evolved from a static to dynamic 
hierarchical one in which the new progenies acquire 
the ability of self-renewal through de-differentiation, 
as well as reversal of differentiated cells (48). In 
addition to this, the theory of clonal evolution, which 
emerged recently, demonstrated the acquisition of self-
renewal capabilities by non-CSC populations within a 
tumour (49,50). This interconverison ability is likely to 
be acquired through oncogenic transformation (49). 
These recent advances, identified through extensive 
research on leukaemic SC, further establishes the 
importance of developing strategies that target both 
CSC and their progenies as both contribute to the 
development of therapy resistant cancers (48). 
 
Epithelial-Mesenchymal Transition (EMT) and 
CSC  
 
EMT refers to the transition during which epithelial 
cells lose their apico-basal polarity, acquire migration 
capability and transform into cells with a more 
mesenchymal phenotype (51). This important process 
is essential in embryonic development and has also 
been implicated in initiation and progression of tumour 
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metastasis (52,53). Thus, during this reversible process 
carcinoma cells acquire mesenchymal gene expression 
patterns and properties (47).  
 
Numerous data has documented the presence of EMT 
in malignant cells in vitro, however its significance in 
human cancer tissues has remained a matter of debate. 
This is due to the difficulty in distinguishing stromal 
cells and other tumour associated fibroblasts from 
individual mesenchymal cells derived from epithelial 
tumour cells by EMT (52). However, Prall et al. have 
now demonstrated the existence of aggregated 
colorectal cancer cells detaching from the main tumour 
mass into adjacent stroma which poses EMT 
characteristics (54). This supports the concept that 
cancer cells with EMT properties are present at the 
invasive fronts of human tumours, which is the 
immediate interphase for tumour and stromal 
signalling from which metastasis occurs (52). 
 
Clinical Implications 
 
Current chemotherapeutic agents generally target 
actively dividing cells, leading to  reduction in tumour 
bulk at certain time points during treatment but fail to 
eradicate the relatively dormant CSC (55). Following 
treatment, SC normally remain inactive for some time; 
however the change in the tumour microenvironment 
along with acquired genetic transformations that occur 
after initial treatment may later trigger the 
development of a more aggressive SC phenotype (56). 
In well differentiated thyroid cancers, often tumour 
cells demonstrate sensitivity towards initial radioactive 
iodine treatment. In those that recur presumably, the 
previously radio avid cells, acquire changes that 
reduce their sensitivity towards later treatment. As 
tumours are composed of heterogenous groups of 
cells, with SC thought to be responsible for recurrence, 
it is reasonable to assume that we should change our 
perspective of how we manage malignant tumours in 
the future. Designing agents that would be able to 
target both cancer and CSC will hopefully result in 
more effective treatment. Identifying the pathways 
involved in this respect may open avenues for the 
development of more targeted therapy in cancer 
management.  
 
The development of resistance in cancer cells towards 
chemotherapeutic agents may partly be attributed to 
the presence of cells that are able to pump out these 
drugs. This efflux property, which is the most widely 
studied aspect of multidrug resistance (MDR) in 
cancer cells, is due to the overexpression of the ATP-
binding cassette (ABC) transporters that reside in the 
transmembrane region of the cells. This feature has 
been exploited to isolate a CSC population with a 
distinct phenotype known as side population (SP) 
cells. This subpopulation of cell was first identified by 
Goodell et al. (57). Using the SP assay, SC have been 
successfully isolated from benign and malignant 
thyroid tissues and cells lines (42,58). There have been 
approaches involving nanoparticle administration 
aimed at inhibiting the activity of these transporters as 
means of overcoming drug resistance in cancer cells 
(59). 
 
The presence of distant metastases denotes stage IV 
disease with lowest survival rate. Evidence is now 
accumulating that relates EMT and prognosis. 
Expression of transcription factors involved in EMT 
such as Snail and Zeb2 are poor prognostic markers in 
hepatocellular (60) and ovarian carcinoma (61) 
respectively. Activation of EMT itself has been linked 
to poor prognosis in colorectal carcinoma (62). In 
addition to this, EMT markers have also been linked to 
tumour recurrence, which generally indicates poor 
prognosis in metastatic breast cancer patients (63). 
Celina and Buehler et al.  have also found a correlation 
between the presence ZEB1, SNAIL and TWIST 
transcription factors and high grade thyroid cancers 
(64). Defining and targeting the appropriate pathways 
involved in EMT will potentially broaden treatment 
options for cancers. 
 
Stem Cells in Benign Tumours 
 
The role of normal SC in the initiation and 
development of benign tumours has been gaining 
attention. In the pathogenesis of benign prostatic 
hyperplasia, in addition to the complex interaction of 
growth stimulation, apoptosis and cell proliferation, 
SC have been shown to play a major role (65). 
Understanding the behaviour of SC in normal and 
benign diseases, may allow us to identify a suitable 
focused treatment in order to minimise harm to 
surrounding normal tissues. 
 
Stem Cells in Regenerative Medicine for 
Hypothyroidism 
 
While the role of CSC is becoming more popular and 
its therapeutic potential widely researched to further 
improve the outcome of thyroid cancers, the role of 
normal SC as a regenerative tool in the management of 
hypothyroidism (primary or secondary) is still in its 
infancy. Even though stem cells from normal thyroid 
tissues have been isolated and characterised, their role 
as a cellular therapy has never been assessed. 
Hypothyroidism is a common condition and thyroid 
regeneration therapy could possibly be an alternative 
to medication. Thyroid SC transplantation post total 
thyroidectomy could potentially avoid the need for 
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administration of lifelong thyroxine, with a potential 
impact on both quality of life and healthcare costs. 
 
Conclusion 
 
In conclusion, knowledge of the presence of SC 
residing in thyroid tissues and cell lines has sparked 
new ideas and avenues in search for a cure for thyroid 
diseases, specifically anaplastic and recurrent cancers. 
Further studies are needed to determine if targeting 
thyroid CSC will provide a platform on which to build 
new more effective options for the treatment of this 
group of thyroid cancers that currently have poor 
prognostic outcomes. 
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